EUVIMEDEUVIMED entdecken
Crossref

Novel concepts of treating vascular inflammation underlying neonatal lung diseases

Arvind Sehgal iD, Steven P Garrick iD, Marcel F Nold, Claudia A Nold-Petry

Journal of Applied Physiology · 2023

DOI: 10.1152/japplphysiol.00549.2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Physiology, 2023. Verfasst von Arvind Sehgal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Glucocorticoids, Bronchopulmonary Dysplasia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 103 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bronchopulmonary dysplasia (BPD) is the most common sequela of prematurity. Although multifactorial in etiology, there is increasing evidence that fetal growth restriction (FGR) and antenatal exposure of the fetus to inflammation play important roles in the postnatal pathophysiology of BPD. Recent studies have focused on disrupted angiogenesis and its influence on alveolarization. Although there are multiple mechanistic links, inflammation is known to be a key driver of this disruption, affecting pulmonary arterial circulation. Although postnatal corticosteroids are commonly used in extremely premature infants to treat inflammation, aimed at obviating the need for intubation and mechanical ventilation or to facilitate extubation, the use of dexamethasone has not reduced the incidence of BPD. Here, we summarize current knowledge on alternative anti-inflammatory treatment options, which have shown promising outcomes either preclinically or clinically. These include supplementation with vitamins C and E (antioxidants), ω-3 polyunsaturated fatty acids, pentoxifylline, anti-inflammatory cytokines of the IL (interleukin)-1 family, namely IL-1 receptor antagonist and IL-37, and the beneficial properties of breast milk. Evaluating these alternative treatments, either individually or as combination therapies in randomized controlled trials stands to immensely benefit the clinical outlook, particularly regarding BPD, for extremely premature infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucocorticoidsBronchopulmonary DysplasiaInfant, NewbornInfantFemalePregnancyHumansDexamethasoneAnti-Inflammatory AgentsInflammation

Stichwörter der Autor:innen

anti-inflammatory treatmentbronchopulmonary dysplasiafetal growth restrictioninflammationtranslational research

Substanzen

GlucocorticoidsDexamethasoneAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia.
  • Department of Paediatrics, Monash University, Melbourne, Victoria, Australia.
  • Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.

ORCID-Profile: Arvind Sehgal, Steven P Garrick

Zitieren

APA

Sehgal, A., Garrick, S. P., Nold, M. F., & Nold-Petry, C. A. (2023). Novel concepts of treating vascular inflammation underlying neonatal lung diseases. Journal of Applied Physiology. https://doi.org/10.1152/japplphysiol.00549.2022

Vancouver

Sehgal A, Garrick SP, Nold MF, Nold-Petry CA. Novel concepts of treating vascular inflammation underlying neonatal lung diseases. Journal of Applied Physiology. 2023. doi:10.1152/japplphysiol.00549.2022

BibTeX
@article{Sehgal2023,
  author = {Sehgal, Arvind and Garrick, Steven P and Nold, Marcel F and Nold-Petry, Claudia A},
  title = {Novel concepts of treating vascular inflammation underlying neonatal lung diseases},
  journal = {Journal of Applied Physiology},
  year = {2023},
  doi = {10.1152/japplphysiol.00549.2022}
}
Kostenlos starten →